Complement - mediated diseases
搜索文档
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Globenewswire· 2025-11-13 05:12
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annexon. In addit ...
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
Businesswire· 2025-11-11 21:30
About Omeros Corporation Nov 11, 2025 8:30 AM Eastern Standard Time Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 Share SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to di ...